Nexalin technology initiates fda q-submission process for gen-2 sync following encouraging data and preliminary fda feedback

Company initiates formal regulatory engagement on trial design for alzheimer's, dementia, and mci indications company initiates formal regulatory engagement on trial design for alzheimer's, dementia, and mci indications
NXL Ratings Summary
NXL Quant Ranking